Clinical Trials Logo

Clinical Trial Summary

Many children with cancer are diagnosed in early childhood, and as such, will likely miss key social experiences such as participation in preschool or kindergarten, playing on playgrounds, and other normative experiences. In typically-developing children, it is known that these experiences - and the skills that are learned during them - are critical to later well-being. Very little is known about the psychological functioning of young children with cancer, as studies have predominantly focused on those who are older (at least 8 years of age). This study will explicitly assess social functioning in preschool-aged children with cancer and follow the development of their social functioning from the end of treatment into survivorship. The goals of this pilot study are to begin to assess the impact of missed early childhood social experiences, as well as the interaction with developing neurocognitive problems. PRIMARY OBJECTIVE: Explore the impact of cancer in the central nervous system on social functioning of young children (ages 4-6) after completion of therapy.


Clinical Trial Description

Participants will be evaluated using the same or similar questionnaires at two time points. The first assessment will take place when they are 6-12 months post the end of treatment. Participants and their parents/legal guardian will complete an assessment of social and cognitive functioning by completing questionnaires about social, emotional, behavioral, and executive functioning. If the study participant agrees, they will identify another adult (that is, teacher or daycare employee) who may be contacted to complete questionnaires about the participant's social and behavioral functioning. A follow-up study visit will occur about two years later. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03086421
Study type Observational
Source St. Jude Children's Research Hospital
Contact Victoria W. Willard, PhD
Phone 866-278-5833
Email referralinfo@stjude.org
Status Recruiting
Phase
Start date July 11, 2017
Completion date September 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1
Recruiting NCT04738162 - Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Supratentorial Brain Tumors Phase 2
Not yet recruiting NCT06093165 - RE-irradiation of Diffuse MIdline Glioma paTients N/A
Recruiting NCT05298995 - GD2-CAR T Cells for Pediatric Brain Tumours Phase 1
Not yet recruiting NCT05553899 - PET-MRI in Paediatric Brain Tumours N/A
Recruiting NCT05709522 - Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients
Recruiting NCT04722237 - Acceptance and Commitment Therapy for Neuro-Oncology Wellbeing N/A
Recruiting NCT06309251 - Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
Recruiting NCT04670016 - HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers
Active, not recruiting NCT03361033 - Components of Social Functioning in Survivors of Pediatric Brain Tumors
Active, not recruiting NCT04525014 - RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors Phase 1
Recruiting NCT05672043 - Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
Completed NCT03871686 - Promotion of Well-being of Young Adult Brain Cancer Survivors N/A
Withdrawn NCT04019470 - Immunomodulation Analysis of Radiation Therapy in Pediatric Malignant Brain Tumors
Active, not recruiting NCT04023669 - Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors Phase 1
Suspended NCT05169944 - Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors Phase 1